These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 6695159)

  • 1. A clinical study of moxalactam in the treatment of infections due to gram-negative bacilli.
    DeMaria A; McCabe WR
    Scand J Infect Dis; 1984; 16(1):83-97. PubMed ID: 6695159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical evaluation of moxalactam: evidence of decreased efficacy in gram-positive aerobic infections.
    Salzer W; Pegram PS; McCall CE
    Antimicrob Agents Chemother; 1983 Apr; 23(4):565-70. PubMed ID: 6222696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective evaluation of moxalactam therapy for gram-negative bacillary meningitis.
    Rahal JJ; Simberkoff MS; Landesman SH
    J Infect Dis; 1984 Apr; 149(4):562-7. PubMed ID: 6725990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Moxalactam therapy for gram-negative bacillary meningitis.
    Rahal JJ
    Rev Infect Dis; 1982; 4 Suppl():S606-9. PubMed ID: 6218572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Moxalactam therapy for neonatal meningitis due to gram-negative enteric bacilli. A prospective controlled evaluation.
    McCracken GH; Threlkeld N; Mize S; Baker CJ; Kaplan SL; Faingezicht I; Feldman WE; Schaad U
    JAMA; 1984 Sep; 252(11):1427-32. PubMed ID: 6381775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cefotaxime in septicaemia and severe infections due to multiresistant Gram-negative bacilli (author's transl)].
    Dureux JB; Canton P; Roche G; Weber M; Gérard A
    Nouv Presse Med; 1981 Feb; 10(8):601-6. PubMed ID: 6259602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Moxalactam therapy of serious infections.
    Van der Auwera P; Clumeck N; Van Laethem Y; Vanhoof R; Butzler JP
    Infection; 1983; 11(4):212-8. PubMed ID: 6618677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of aztreonam in the treatment of serious infections due to multiresistant gram-negative organisms, including Pseudomonas aeruginosa.
    Scully BE; Neu HC
    Am J Med; 1985 Feb; 78(2):251-61. PubMed ID: 4038574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Moxalactam for treatment of nosocomial infections.
    Winston DJ; Kurtz TO; Young LS; Busuttil RW
    Rev Infect Dis; 1982; 4 Suppl():S650-S655. PubMed ID: 6218578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of lamoxactam in the treatment of severe bacterial infections.
    Bouza E; Martínez-Beltrán J; Rodríguez-Creixems M; Loza E; Pérez del Rio J; Guerrero A; Hospital JS
    Chemotherapy; 1983; 29(5):373-83. PubMed ID: 6617297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gentamicin. Clinical and pharmacological studies.
    Holloway WJ
    Int Z Klin Pharmakol Ther Toxikol; 1970 May; 3(2):122-7. PubMed ID: 4913081
    [No Abstract]   [Full Text] [Related]  

  • 12. Moxalactam (LY127935) in treatment of meningitis due to gram-negative bacilli.
    Fisher JF; Carter MJ; Parsons J; Rissing JP
    Antimicrob Agents Chemother; 1981 Feb; 19(2):218-21. PubMed ID: 6214985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of latamoxef as initial therapy of bone and joint infections in childhood.
    Aronoff SC; Scoles PV; Reed MD; Kelley F; Husak M; Blumer JL
    Chemotherapy; 1984; 30(5):337-44. PubMed ID: 6333322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Moxalactam in the treatment of pediatric infections.
    Yogev R; Schreiber M; Gardner S; Shulman ST
    Am J Dis Child; 1982 Sep; 136(9):836-9. PubMed ID: 6214182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ticarcillin plus clavulanic acid versus moxalactam therapy of osteomyelitis, septic arthritis, and skin and soft tissue infections.
    Siebert WT; Kopp PE
    Am J Med; 1985 Nov; 79(5B):141-5. PubMed ID: 4073082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy of moxalactam with emphasis on infections due to multidrug-resistant organisms in patients with renal insufficiency.
    Trager GM; Panwalker AP; Malow JB; Porembski PE; Ramirez CA; Zar FA
    Chemotherapy; 1981; 27(4):287-95. PubMed ID: 6454542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical evaluation of moxalactam in the treatment of respiratory tract infections, hepatobiliary infections, and septicemia.
    Saito A
    Rev Infect Dis; 1982; 4 Suppl():S623-8. PubMed ID: 6218575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Moxalactam (latamoxef). A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Carmine AA; Brogden RN; Heel RC; Romankiewicz JA; Speight TM; Avery GS
    Drugs; 1983 Oct; 26(4):279-333. PubMed ID: 6354685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of moxalactam in the treatment of serious infections due to multi-resistant organisms.
    Srinivasan S; Francke EL; Ortiz-Neu C; Prince AS; Neu HC
    Infection; 1983; 11(6):291-5. PubMed ID: 6668067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carbenicillin therapy of gram-negative bacilli infections.
    Bodey GP; Rodriguez V; Luce JK
    Am J Med Sci; 1969 Jun; 257(6):408-14. PubMed ID: 4893148
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.